For US Healthcare Professionals US Prescribing Information Medication Guide CHOOSE INDICATIONDrugDrug name X NVAF: Reducing stroke risk Chronic CAD/PAD: Reducing the risk of major CV events DVT/PE: Treatment DVT Prophylaxis: After hip/knee replacement surgery Home Clinical Trial COMPASS patient population COMPASS study design Efficacy Profile Chronic CAD/PAD additional outcomes Chronic CAD/PAD major CV events Safety Profile Chronic CAD/PAD safety profile Chronic PAD subgroup safety profile Dosing Home Extensive Evidence Efficacy Profile ITT population Safety, as-treated population Real-world evidence: Stroke risk reduction Safety Profile Safety profile Real-world evidence: Major bleeding Real-world evidence: GI bleeding Real-world evidence: ICH bleeding Real-world evidence: Fatal bleeding Dosing Dose information Renal information Home Extensive Evidence Efficacy Profile Initial treatment Reduction in the risk of recurrence Real-world outcomes Safety Profile Principal safety outcome in initial treatment Major bleeding in initial treatment Safety outcome in recurrence risk reduction Real-world outcomes Dosing Dose information Starter Pack Home Extensive Evidence Efficacy Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Safety Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Dosing DOSING SWITCH AND MANAGEMENT Switching to/from XARELTO® Bleed management considerations Temporary discontinuation Other administration options ACCESS AND SUPPORT Formulary finder Janssen CarePath Program Janssen Prescription Assistance RESOURCES Reprints Patient resources Professional resources Other resources FAQs SEARCH XARELTO® DOSING: ALL INDICATIONS Search Important Safety Information US Prescribing Information Medication Guide For Non-US Visitors Patient Site Change Indication Choose Indication NVAF: Reducing stroke risk Extensive evidence Efficacy profile Safety profile Dosing Chronic CAD/PAD: Reducing the risk of major cardiovascular events Clinical Trial Efficacy profile Safety profile Dosing DVT/PE: Treatment Extensive evidence Efficacy profile Safety profile Dosing DVT Prophylaxis: After hip/knee replacement surgery Extensive evidence Efficacy profile Safety profile Dosing Home Clinical Trial COMPASS patient population COMPASS study design Efficacy Profile Chronic CAD/PAD additional outcomes Chronic CAD/PAD major CV events Safety Profile Chronic CAD/PAD safety profile Chronic PAD subgroup safety profile Dosing Home Extensive Evidence Efficacy Profile ITT population Safety, as-treated population Real-world evidence: Stroke risk reduction Safety Profile Safety profile Real-world evidence: Major bleeding Real-world evidence: GI bleeding Real-world evidence: ICH bleeding Real-world evidence: Fatal bleeding Dosing Dose information Renal information Home Extensive Evidence Efficacy Profile Initial treatment Reduction in the risk of recurrence Real-world outcomes Safety Profile Principal safety outcome in initial treatment Major bleeding in initial treatment Safety outcome in recurrence risk reduction Real-world outcomes Dosing Dose information Starter Pack Home Extensive Evidence Efficacy Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Safety Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Dosing DOSING SWITCH AND MANAGEMENT Switching to/from XARELTO® Bleed management considerations Temporary discontinuation Other administration options ACCESS AND SUPPORT Formulary finder Janssen CarePath Program Janssen Prescription Assistance RESOURCES Reprints Patient resources Professional resources Other resources FAQs SEARCH XARELTO® DOSING: ALL INDICATIONS
NVAF: Reducing stroke risk Extensive evidence Efficacy profile Safety profile Dosing Chronic CAD/PAD: Reducing the risk of major cardiovascular events Clinical Trial Efficacy profile Safety profile Dosing DVT/PE: Treatment Extensive evidence Efficacy profile Safety profile Dosing DVT Prophylaxis: After hip/knee replacement surgery Extensive evidence Efficacy profile Safety profile Dosing
XARELTO®: Stroke risk reduction in nonvalvular atrial fibrillation (NVAF) WHY WOULDN'T YOU CHOOSE A NOAC WITH EXTENSIVE EVIDENCE IN STROKE RISK REDUCTION? 24-HOUR STROKE RISK REDUCTION1,2 EFFICACY PROFILE PROVEN SAFETY PROFILE1 SAFETY PROFILE ONCE-DAILY dosing* *Taken with evening meal. DOSING TIME AND TIME AGAIN—extensive clinical trial and real-world evidence1,3-17 EXTENSIVE EVIDENCE NOAC = non-vitamin K antagonist oral anticoagulant. General Tags: NVAF: Reducing stroke risk
